ASBP

Aspire is an early-stage biopharma that reverse-merged into the former PowerUp Acquisition Corp SPAC in February 2025, and the numbers show a company with essentially no business yet. FY2025 revenue was $6.20K — not thousands of dollars of product sales in any meaningful sense — against a $24.5M net loss and a -$19.4M operating loss. At $6.21 the market cap is $31.2M, or a nonsensical 5,030x sales; there is no earnings, sales, or asset base here to value, so the price is pure speculation on a single unapproved drug candidate. Gross profit is literally negative on a few thousand dollars of revenue.

The balance sheet is already broken. Stockholders' equity is -$6.38M (liabilities of $7.69M against $1.31M of total assets), retained earnings are -$27.3M, and cash is just $1.00M against a -$4.92M annual operating burn — roughly two to three months of runway. Management's own MD&A concedes Aspire 'has incurred net losses in every year since its inception,' 'anticipates that it will continue to incur substantial and increasing net losses,' and 'will require substantial additional financing… a failure to obtain this necessary capital when needed could force Aspire to delay, limit, reduce or terminate its product development.' With negative equity and a micro cash balance, that financing will be highly dilutive to the 5.02M share count (already down ~90% YoY, implying a reverse split) — a structural headwind for any equity holder.